The 2025 ESMO Lifetime Achievement Award will be presented to Rolf A. Stahel at the ESMO 2025 Opening Ceremony. Rolf  Stahel is President of our ETOP IBCSG Partners Foundation and a leading figure in thoracic oncology and cancer research. esmo.org/about-esmo/awa…

How reliable is a result from a single biopsy when tumor heterogeneity varies not only between different biopsy sites but even within the same tumor? Insights from Solange Peters, Giannis Mountzios & Jacob sands explain why this complexity can impact treatment decisions ⬇️

Our Chairs Alfredo Addeo MD & Solange Peters warmly invite you to join this year’s ILCS – live online or in person in Lausanne, Switzerland. The agenda is now online: Explore what’s in store – from targeted therapies to evolving strategies in early and advanced-stage lung cancer ⬇️

FDA approves zongertinib 120mg po daily for previously treated advanced #HER2 NSCLC. In the phase 1b Beamion-LUNG 1 study NEJM, RR 71% (42% post ADC), DOR 14.1m, intracranial RR 41%. Main toxicity is diarrhea (56%, 48% grade 1), no ILD. fda.gov/drugs/resource…

2L+ Zongertinib for HER2 NSCLC a great step forward 👉 Clear clinical activity 👉 Much better TRAEs than 1G TKIs, and 🔽 diarrhoea than BAY88 rival 👉 1L trials ongoing: best place for this agent IMO 👉 Optimal sequencing with ADC unknown 👉 🇬🇧 needs access to HER2 drugs #LCSM

Utility of NGS for NSCLC in a real-world South Indian population reported The Oncologist. NGS testing associated with better outcomes - PFS and OS - with longer survival when treatment matched to NGS. Biomarker testing essential for NSCLC globally. academic.oup.com/oncolo/article…

Are autoAbs implicated in ICI response? nature⁩ - REAP assay (rapid extracel Ag profile, ab-exoproteome interaction) in 374pts&131 controls - type I IFN autoAB= ⬆️response - BMPR1A&BMPR2 autoAB= ⬇️response ⁦Fred Hutch Cancer Center⁩ ⁦OncoAlert⁩ #LCSM nature.com/articles/s4158…

Check out the agenda for the upcoming ILCS on 26ᵗʰ September 2025. Join and connect with experts from across the globe, live in Lausanne or online, to discuss the latest advances in lung cancer treatment and care. Let's bridge the gap in thoracic oncology together 🌎

Look before you vape! #lcsm the black areas on these images are the lungs and much of the white patchy stuff in them should not be there and is not good!

Use of bronchial wash fluid for NGS testing in NSCLC reported JCO Precision Oncology. Concordance between bronchial wash and tissue was 94%. ctDNA from bronchial wash was more comparable to tissue than plasma in this study. ascopubs.org/doi/10.1200/PO…

Ph II PAVE trial intercalated avelumab (from c3) plt-etop in ES SCLC EJCANCER - 55pts - mPFS 5.8m mOS 10.3m ORR 69.1% - 1yr PFS 12% (primary endpt, not met) Important academic study led by #helleniconcgroup Helena Linardou Giannis Mountzios OncoAlert #LCSM sciencedirect.com/science/articl…

You can join us at the ILCS onsite in the beautiful city of Lausanne or virtually online! If you're joining us in person, you can find us at the CHUV Lausanne on 26ᵗʰ September 2025 from 9.45 AM CEST. We look forward to seeing you there 👋

Catch up with Solange Peters on IO combos and her thoughts based on current ESMO guidelines. How are anti-CTLA4 bringing progress and how do we manage toxicity & STK11/KEAP1 co-mutations? Check out these important aspects during her discussions with Patrick Forde & Jordi Remon

Ready for another insightful ILCS? 🫁 Last year’s summit brought together leading voices in thoracic oncology – and this year, we’re continuing the conversation with another outstanding lineup of experts. Mark your calendars! 🗓️ 26ᵗʰ September 2025 Explore and register ⬇️

B7-H3 = consistently high across all #SCLC subtypes (A/N/P/I) — unlike DLL3 & SEZ6! ✅ Uniform high RNA expression ✅ Backs B7-H3-targeted ADCs & TCEs for unselected SCLC ✅ Ifinatamab deruxtecan: 54.8% ORR in ES-SCLC! #LungCancer #PrecisionOncology #ADCs #CancerResearch

Join us and Rami Manochakian MD, FASCO Cancer Education from the USA, at this year's International Lung Cancer Summit on 26ᵗʰ September. Dr. Manochakian will present the latest breakthroughs and evolving strategies in SCLC management across all stages. Reserve your place today and register now ⬇️

How can timely detection and tailored therapy improve outcomes in HER2 and MET altered NSCLC? Hear insights from Stephanie Saw of Singapore at the International Lung Cancer Summit on 26ᵗʰ September. Explore the latest evidence and register now ⬇️

Looking forward to speaking at #ILCS25 this year, lots of exciting data for HER2 and MET alterations in NSCLC (mutations and beyond). Gonna be a busy September but no better place to conclude than in beautiful Geneva! 🇨🇭🧀🏞️🍫 International Lung Cancer Summit Alfredo Addeo MD

From trial data to real-world practice, Noemi Reguart will explore how ADCs are transforming and expanding treatment options in lung cancer, and what every clinician needs to know right now. Join her at the International Lung Cancer Summit on 26ᵗʰ September. Details & register ⬇️

The Lung Cancer Summit is a forum for you to navigate the latest developments and openly discuss daily challenges in Lung Cancer care with fellow thoracic experts 🤝 Get involved: share your questions, insights, patient cases & together, drive progress for patients worldwide ⬇️